Email: cspc@cspc.cn
Email: cspc@cspc.cn
August 30, 2022
“SYHX2009” (the “Product”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.
The Product is a Class 1 innovative chemical drug developed by the Group with various patent applications submitted. The Product is a selective NTRK and ROS1 dual inhibitor. The indications for this clinical trial approval is solid tumor with NTRK or ROS1 gene rearrangement/fusion and positive resistance mutations. The pre-clinical studies have shown that the Product has excellent in vivo and in vitro activity and good safety, providing a promising clinical development value.
